CHRIS RECKNOR, M.D.

Education

M.D. Medical University of South Carolina, Charleston, SC (1991)
B.A. Furman University, Greenville, SC (1987)

Residency:

Internal Medicine, Medical University of South Carolina, Charleston, SC (1991 – 1995)

Licensure

Georgia

Professional Experience

Medical Director:
United Osteoporosis Centers
2350 Limestone Parkway
Gainesville, GA 30501
770-534-5154
(1998 - present)

Private Practice:
Chris Recknor, MD PC
Internal Medicine and Metabolic Bone Disorders
2350 Limestone Parkway N.E.
Gainesville, GA 30501
770-534-5154
(1998 - present)

Private Research Facility:
Center for Advanced Research and Education (CARE)
2350 Limestone Parkway, N.E.
PO Box 908063
Gainesville, GA 30501
(2002 - present)

Medical Software
IONmed Systems
2350 Limestone Parkway, N.E.
Gainesville, GA 30501
(2006 - present)

Adjunct Assistant Professor:
Clemson University – Department of Bioengineering
202 Biosystems Research Center
Clemson, SC 29634
(2002 - present)

Chief Medical Consultant:
PharmData, Inc.
2440 Sandy Plains Road NE, Building 9
Marietta, GA 30066
(1995 – 2003)

Emergency Room Physician:

Lanier Park Hospital
675 White Sulphur Road
Gainesville, GA 30505
(1997-1998)

Rabun County Memorial Hospital
394 Ridgecrest Circle
Clayton, GA 30525
(1997-1998)

Chestatee Regional Hospital
227 Mountain Drive
Dahlonega, GA 30533
(1997-1998)

Fannin Regional Hospital
2855 Old Highway 5
Blue Ridge, GA 30513
(1997-1998)

Chatuge Regional Hospital
110 S Main Street
Hiawassee, GA 30546
(1997-1998)

Group Practice:

Northeast Georgia Diagnostic Clinic
Internal Medicine Department
Gainesville, GA 30501
(1995-1997)

Staff Privileges:

Northeast Georgia Medical Center
743 Spring Street, NE
Gainesville, GA 30501
(1995-present)

Gainesville Surgery Center
1945 Beverly Road
Gainesville, GA 30501
(2004-present)

Mountainside Medical Center
1266 East Church Street
Jasper, GA 30143
(2001-2006)

Current Affiliations

Regional Speaker – Merck, West Point, PA (1996 – present)
National Speaker – Novartis Pharmaceuticals Corporation, East Hanover, NJ (1996 – present)
Georgia State Representative – National Osteoporosis Foundation, Atlanta, GA (1997 – present)
Clinical Internal Medicine Advisory Board – Eli Lilly, Indianapolis, IN (2004 - present)
Consultants Network on Osteoporosis - Novartis Pharmaceuticals Corporation (1998 – present)
Women's Health Advisory Board – Eli Lilly, Indianapolis, IN (1998 – present)
Southeast Osteoporosis Board – Procter & Gamble, Cincinnati, OH (2003 – present)
National News Media Spokesperson – GSK/Hoffmann-La Roche (2004 – present)
National Spokesperson - Novartis Pharmaceuticals Corporation - Reclast (2007 – present)
International Speaker – MediUSA – SpinoMed III (2009 – present)
Peer Reviewer – Aging Health Journal (2009-present)

Certification

Diplomate of the American Board of Internal Medicine
Certified Clinical Densitometrist
Certified Clinical Peripheral Densitometrist

Pharmaceutical Clinical Trials

Amgen	Primary Investigator: Prospective Observational Study to Evaluate Persistence with Prolia in Postmenopausal women with Osteoporosis in Routine Clinical Practice. (8/2011 to present)
	Primary Investigator: A Phase 3b randomized, open-label study evaluating the safety and efficacy of two osteoporosis treatments in postmenopausal women sub-optimally treated with daily or weekly bisphosphonates. (6/2009 – present)
	Primary Investigator: A Phase 2 randomized, placebo-controlled, multi-dose study to determine the efficacy, safety and tolerability of an investigational medication in the treatment of postmenopausal women with low bone mineral density. (4/2009 - present)
	Primary Investigator: A Phase 3 open-label study assessing the long-term safety and efficacy of study medication. (8/2007 – present)
	Primary Investigator: A Phase 3b open-label study assessing the immunogenicity and safety of study medication via two delivery methods in subjects with low bone mineral density. (5/2007- 12/2008)
	Primary Investigator: A Phase 3 study evaluating the safety and efficacy of transitioning therapy from a bisphosphonate to study medication in postmenopausal women with low bone mineral density. (10/2006 – 5/2008)

	Primary Investigator: A Phase 3 double-blind study comparing the efficacy of study medication versus a bisphosphonate in postmenopausal women with low bone density. (4/2006 – 2/2008)
	Primary Investigator: A Phase 3 study on the evaluation of medication in the treatment of postmenopausal osteoporosis (7/2004 – 9/2008)
Aventis Pharmaceuticals	Primary Investigator: Open-label study to determine how prior osteoporosis therapies influence effectiveness of a third osteoporosis treatment. (5/2004 – 1/2007)
Daiichi- Sankyo	Primary Investigator: A randomized, Double- Blind, Placebo and Active comparator- controlled study of investigational product for the treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy. (10/2011- 3/2013).
DOV Pharmaceutical	Primary Investigator: A Phase 3 multi-center, standard of care study to evaluate the long-term safety of study drug for the treatment of chronic low back pain. (2/2006 – 4/2007)
	Primary Investigator: A Phase 3 multi-center study for treatment of low back pain. (6/2005 – 5/2006)
Eli Lilly	Primary Investigator: Effect of study drug on Femoral Neck fracture Healing. (12/2011 to present).
	Primary Investigator: A phase 2 randomized Study to Investigate the Efficacy and Safety of Study Drug versus Placebo in Older Patients Undergoing Elective Total Hip Arthroplasty. (8/2011 to present).
	Primary Investigator: A Phase 2 randomized, placebo-controlled study to evaluate the dose response of an investigational medication in the treatment of postmenopausal women with low bone mineral density. (08/2010 – present).
	Primary Investigator: A multi-center study comparing the effects of Teriparatide with those of Risedronate on Lumbar Spine Bone Density in Men and Women with recent hip fracture. (7/2010 to present).
	Primary Investigator: A Phase 4, multicenter, randomized, stratified, double-blind, double-dummy, active comparator-controlled study comparing iliac crest bone biopsies in postmenopausal women on 12 months of treatment. (6/2009-present).

Primary Investigator: A Phase 3, open-label study in men and women assessing their perception of a device used to self administer a medication. (2/2007 – 1/2008)

Primary Investigator: A Phase 1, open label in men and women evaluating the bioavailability of an investigational medication in subjects with Rheumatoid Arthritis. (10/2007 – 9/2008)

Primary Investigator: A Phase I study on the effects of study medication on osteoarthritis-related biomarkers. (1/2006 – 3/2007)

Primary Investigator: A phase 3 study on the comparison of the efficacy and safety of study medication versus in postmenopausal women with osteoporosis. (10/2006 – 1/2008)

Primary Investigator: A Phase 3 study on the effects of study medications compared with a bisphosphonate on back pain in postmenopausal women with osteoporotic fractures. (4/2006 – 9/2010)

Primary Investigator: Forteo Observation study. (4/2004 – 11/2010)

Primary Investigator: A Phase 3 study to assess the effects of treatment on fracture incidence and on invasive breast cancer in postmenopausal women with osteoporosis or low bone density. (3/2004 – 1/2010)

Primary Investigator: A Phase 4 multi-center study in postmenopausal women previously treated for osteoporosis. (9/2003 – 10/2006)

Primary Investigator: A multi-center study in assessing bone mineral density in glucocorticoid-induced osteoporosis. (8/2003 – 6/2007)

Primary Investigator: A Phase 4 multi-center study in post-menopausal women with osteoporosis. (8/2002- 12/2004)

Sub-Investigator: A Phase 2 study evaluating PTH analog and acute fracture healing. (12/2004 – 12/2006)

Endoceutics — Primary Investigator: A placebo-controlled study to determine the effects of a topical medication against vaginal atrophy in postmenopausal women. (9/2007 – 5/2008)

GlaxoSmithKline — Primary Investigator: A study assessing the effect of study medication versus placebo on LS BMD in men with osteoporosis. (3/2006 – 9/2008)

Hoffmann La-Roche — Primary Investigator: A study evaluating the effect on renal function of study medication administered as an i.v. bolus injection compared to an

	i.v. infusion, and an approved oral treatment administered once weekly, in postmenopausal women with osteoporosis at high risk for renal disease. (6/2007 – 3/2010)
	Primary Investigator: Multi-center study in postmenopausal osteoporosis. (8/2002 – 6/2005)
	Primary Investigator: Open-label extension study of two different dosing schedules of treatment in women with postmenopausal osteoporosis. (3/2005 – 6/2008)
	Primary Investigator: A Phase 4 study to investigate patient preference on dosing in women with postmenopausal osteoporosis treated with study medication and a bisphosphonate. (5/2006 – 10/2007)
	Primary Investigator: Multi-center study to compare efficacy and safety of two different medications in postmenopausal osteoporosis. (3/2005 – 2/2007)
Merck & Co.	Primary Investigator: A 2-part study to compare safety and efficacy of two treatments in patients with osteoarthritis. (2/2004 - 2/2005)
	Primary Investigator: A study assessing the safety and efficacy of study medication for the treatment of sarcopenia in patients recovering from a hip fracture. (2004 - 2005)
Nordic Bioscience	Primary Investigator: A Phase 3 multi-center study to evaluate the efficacy and safety of study medication in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D. (6/2007 – 10/2009)
Novartis Pharmaceuticals Corporation	Primary Investigator: A Phase 4, multi-center, double-blind, trial to evaluate the efficacy and safety of study medication administered in combination or alone in patients with Stage 2 Hypertension. (1/2009-10/2009)
	Primary Investigator: A Phase 2 multi-center study to determine the target dose of an investigational medication in the treatment of acute flares of gout. (11/2008 – 6/2009)
	Primary Investigator: A Phase 3b extension to a previous extension study assessing the long-term safety and efficacy of study medication in the treatment of postmenopausal women with osteoporosis. (6/2008 – 7/2010)

Primary Investigator: A Phase 4, multi-center, double-blind, trial to evaluate the blood pressure lowering efficacy comparing moderate versus aggressive treatment regimen in patients uncontrolled on ARB monotherapy. (3/2008-4/2009)

Primary Investigator: A Phase 3b study to assess the effects of combination of study medication and a daily SC treatment on postmenopausal women with severe osteoporosis. (12/2006 – 4/2009)

Primary Investigator: A Phase 4 multi-center study to evaluate the efficacy of two treatments in patients with stage-2 hypertension. (1/2004 – 3/2005)

Primary Investigator: A Phase 3b multi-center study in patients with overactive bladder. (8/2003 – 12/2004)

Primary Investigator: A Phase 3 multi-center efficacy and safety study comparing two treatments for osteoporosis in men. (10/2003 – 10/2007)

Primary Investigator: A Phase 3 extension of a study assessing the long-term safety and efficacy of study medication in the treatment of postmenopausal osteoporosis. (6/2005 – 3/2010)

Primary Investigator: A Phase 3 multi-center study in the treatment of osteoporosis in postmenopausal women. (4/2002 – 8/2006)

Primary Investigator: A Phase 3 multinational study - preventing subsequent osteoporotic fractures after a hip fracture. (2/2002 – 5/2007)

Primary Investigator: A Phase 3 multinational, multi-center study - to evaluate the efficacy of two treatments in patients with corticosteroid-induced osteoporosis. (6/2004 – 6/2007)

Primary Investigator: A Phase 2b multi-center dose-finding study in postmenopausal women with osteopenia. (06/2004 – 7/2005)

Primary Investigator: A Phase 3b/4 multi-center study examining pain regimens in the management of medication side effects in women with osteoporosis. (12/2004 – 11/2005)

Primary Investigator: A multi-center study to determine the efficacy and safety of two different dosing schedules of osteoporosis treatment in the prevention of bone loss in postmenopausal women with osteopenia. (7/2004 – 4/2008)

Primary Investigator: A Phase 2b extension study to assess safety of selected dose of medication in postmenopausal osteoporosis. (3/2005 – 9/2005)

Pfizer

Primary Investigator: A Phase 4 study of cardiovascular safety in osteoarthritis or rheumatoid arthritis patients with or at high risk for cardiovascular disease comparing study medication with two analgesics. (11/2006 - present)

Procter & Gamble

Primary Investigator: A Phase 3 multi-center, double-blind, double-dummy, randomized, active-controlled, parallel-group study to evaluate a delayed release versus an immediate release bisphosphonate in postmenopausal women. (9/2007-5/2008)

Primary Investigator/Surgeon: To evaluate a cross sectional analysis, comparing the degree of mineralization of the bone from postmenopausal women treated with long-term bisphosphonates. (6/2005-11/2006)

Primary Investigator: A Phase 2 study to evaluate two doses of study medication versus a daily SC treatment on bone turnover markers, pharmokinetics, and safety in postmenopausal women. (10/2006 – 7/2007)

Sub-Investigator: Bone Biopsy Analysis comparison of long-term bisphosphonate therapy and micro-crack damage.

Primary Investigator: Preloading of high dose Bisphosphonate to prevent vertebroplasty-induced fractures. (6/2002 - 2005)

Proctor & Gamble/Sanofi-Aventis Alliance for Better Bone Health

Primary Investigator: A Phase 3 Multi-center study comparing a monthly treatment regimen to a daily regimen in postmenopausal osteoporosis. (9/2005 - 8/2008)

Primary Investigator/Surgeon: Bone Histomorphometry, Microarchitecture and Matrix Structure in patients on long-term bisphosphonate therapy. (7/2005 - 12/2006)

Takeda

Clinical Adjudication Committee Chairman: Takeda Global Research & Development Committee to independently assess and adjudicate all fractures that may occur in the Takeda study. (5/2008-present)

Primary Investigator: A Phase-2, multi-center study to evaluate weekly treatment with study medication in subjects with Type 2 diabetes. (4/2007 – 5/2008)

Primary Investigator: A Phase 3 multi-center study to determine the efficacy and safety of study medication plus an approved treatment, study treatment alone, or the approved treatment alone in subjects with Type 2 diabetes. (6/2007-7/2007)

Primary Investigator: A Phase 3 multi-center study to determine the efficacy and safety of the combination of study medication and an approved treatment in subjects with Type 2 diabetes. (6/2007-8/2007

Ortho-McNeil — Primary Investigator: A Phase 3b multi-center study to determine the efficacy and safety of an investigational pain medication in subjects with acute back pain caused by vertebral compression fractures. (10/2008 – 1/2010)

MEDRAD Interventional/Possis

Sub-Investigator: A registry studying patients treated in the peripheral vascular system using any AngioJet Rheolytic thrombectomy with a variety of catheter lengths. (7/2010-present)

Wyeth-Ayerst — Study physician: Cholesterol adjuvant study in healthy adult and elderly subjects. (2/1994-1/1995)

Study physician: Influenza vaccine study in healthy adult and elderly subjects. (2/1994-1/1995)

Grants

Procter & Gamble — Aquatic therapy versus land-based treatment for adults with osteoporosis and balance dysfunction. (12/2004 – present)

Vertebro-Plasty Versus Gray Ramus Nerve Block for Pain Management of Acute Compression Fractures. (2002-present)

MediUSA — Fracture incidence and musculoskelatal correlates in patients using

SpinoMed III brace versus weighted brace or no brace. (2/2009 – present)

Novartis — Descriptive differences among patients taking i.v. zoledronic acid versus those taking oral bisphosphonates in a real-world osteoporosis clinic setting. (7/2009 – present)

Research Grants

St. Josephs Hospital, The North Georgia College, and Programs Assissting the Community Elderly – (1998-1999)

Participant in study involving 13 Georgia county senior centers to evaluate fracture risk in the elderly population. This study also evaluated physician and patient perceptions of osteoporosis. The goal was to increase awareness of the disease. Additionally, assessment of fracture risk using a multi-disciplinary approach was obtained.

Senior Center Osteoporosis PIXI Evaluation – Atlanta, GA (1999)

SCOPE program - Worked in conjunction with Novartis Pharmaceuticals to increase awareness regarding osteoporosis issues at senior centers by PIXI scans. This program included the development of a computer program to help predict which patients need to have further DXA testing of the hip and spine from PIXI results by using risk factors in addition to the PIXI scan results.

Osteoporosis Programs/Tools

Developed Nonpharmacological Approaches to Reducing Fracture Risk slide deck for Amgen Pharmaceuticals, 2009.

Developed the patented "Bone Safety Evaluation™" with concept of "Functional Risk for Fracture™" – an evaluation tool developed to assess risk for fracture associated with typical movements of everyday life. Recknor C, Grant S. United States Patent: 7556045 - System and method for osteoporosis assessment, 2009. Available at: http://patft.uspto.gov

Developed "Stand Tall" rehabilitation program with nine physical therapy sites, designed for total care of the patient from nutritional counseling to rehabilitation to preventative counseling.

Developed Fracture Risk Assessment Protocol - a protocol that integrates bone density with risk factors to determine potential fracture outcomes.

Developed patent-pending "Osteoporosis Medication Adherence Questionniare ™ (OMAQ)" – a method to assess actual non-adherence and risk for non-adherence with osteoporosis medication, 2005.

Developed Medication Adherence Assessment: A method to assess compliance via analysis of cognitive, lifestyle-health perception, awareness and medication issues, 2005.

Abstracts/Presentations

1. SL Silverman, E Siris, DL Kendler, D Belazi, JP Brown, DT Gold, EM Lewiecki, A Papaioannou, C Simonelli, G Quinn, A Balasubramanian, FM Mirza, P Ho, S Siddhanti, B Stolshek, C RecknoR; Persistence With Prolia® (Denosumab) for 1 Year in Relation to Patient-reported Data: Interim Results From a Prospective Observational Study of Postmenopausal Women With Osteoporosis, ASBMR 2014 Pub. ID: 049183

2. S. L. Silverman • E. Siris • D. L. Kendler • D. Belazi • J. P. Brown • D. T. Gold • E. M. Lewiecki • A. Papaioannou • C. Simonelli • I. Ferreira • A. Balasubramanian • P. Dakin • P. Ho • S. Siddhanti • B. Stolshek • C. Recknor; Persistence at 12 Months With Denosumab in Postmenopausal Women With Osteoporosis: Interim Results From a Prospective Observational Study (conditional acceptance for publication Feb 2014, Osteoporosis International)
3. HK Genant, S Boonen, MA Bolognese, C Mautalen, JP Brown, **C. Recknor**, S Goemaere, K Engelke, Y-C Yang, M Austin, A Grauer, C Libanati; Effect of Romosozumab on Lumbar Spine and Hip Volumetric Bone Mineral Density (vBMD) as Assessed by Quantitative Computed Tomography (QCT) (Accepted Feb 2014 oral presentation at ESCEO Seville 2014)
4. HK Genant, S Boonen, MA Bolognese, C Mautalen, JP Brown, **C. Recknor**, S Goemaere, K Engelke, Y-C Yang, M Austin, A Grauer, C Libanati; Effect of Romosozumab on Lumbar Spine and Hip Volumetric Bone Mineral Density (vBMD) as Assessed by Quantitative Computed Tomography (QCT) (Submitted Jan 2014, EULAR)
5. Jay Magaziner , Denise Orwig, Kenneth Lyles, Lars Nordsletten, Steven Boonen, Jonathan Adachi, Chris Recknor, Cathleen Colon-Emeric, Peter Mesenbrink, Guoquin Su, Christina Bucci-Rechtweg, Rasheeda Johnson, Carl Pieper; Subgroup Variations in Bone Mineral Density Response to Zoledronic Acid Following Hip Fracture, (Submitted Jan 2014, Journal of Bone and Mineral Research)
6. S. L. Silverman, E. Siris, D. L. Kendler, D. Belazi, J. P. Brown, D. T. Gold, E. M. Lewiecki, A. Papaioannou, C. Simonelli, I. Ferreira, A. Balasubramanian, P. Dakin, P. Ho, S. Siddhanti, B. Stolshek, C. Recknor; Persistence at 12 Months With Denosumab in Postmenopausal Women With Osteoporosis: Interim Results From a Prospective Observational Study, (Abstract submitted Dec 2013, Osteoporosis International)
7. David W Dempster, Hua Zhou, Robert R Recker, Jacques P Brown, Michael A Bolognese, **Christopher P Recknor**, David L Kendler, E Michael Lewiecki, David A Hanley, D Sudhaker Rao, Paul D Miller, Grattan C Woodson, III, Robert Lindsay, Neil Binkley, Jahangir Alam, Fangqiu Zhang,Valerie A Ruff, Boris Janos, Kathleen A Taylor; A longitudinal study of Skeletal Histomorphometry in patients On Teriparatide (TPTD) or Zoledronic acid (ZOL), the SHOTZ trial; John H Carstens Memorial Distinguished Orals Session - Osteoporosis Treatment Accepted for presentation Oct 27 2013 American College of Rheumatology
8. JP Brown, MA Bolognese, PR Ho, J Hall, C Roux, HG Bone, S Bonnick, J van den Bergh, I Ferreira, P Ghelani, P Dakin, RB Wagman, **C. Recknor**; Denosumab Leads to Significantly Greater Increases in Bone Mineral Density Than Ibandronate and Risedronate in Postmenopausal Women at High Risk for Fracture Who Were Previously Treated With an Oral Bisphosphonate Who Are at Higher Risk for Fracture (Accepted for presentation for Oct 28, 2013 American College of Rheumatology)
9. HK Genant, S Boonen, MA Bolognese, C Mautalen, JP Brown, **C. Recknor**, S Goemaere, K Engelke, Y-C Yang, M Austin, A Grauer, C Libanati; Romosozumab Administration is Associated with Significant Improvement in Lumbar Spine and Hip Volumetric Bone Mineral Density and Content Compared With Teriparatide (Poster presented Oct 2013, American College of Rheumatology)

10. JP Brown, MA Bolognese, PR Ho, J Hall, C Roux, HG Bone, S Bonnick, J van den Bergh, I Ferreira, P Ghelani, P Dakin, RB Wagman, **C. Recknor**; Denosumab Significantly Increases Bone Mineral Density Compared With Ibandronate and Risedronate in Postmenopausal Women Previously Treated With an Oral Bisphosphonate Who Are at Higher Risk for Fracture Presented Oct 2013 ASBMR
11. HK Genant, S Boonen, MA Bolognese, C Mautalen, JP Brown, **C. Recknor**, S Goemaere, K Engelke, Y-C Yang, M Austin, A Grauer, C Libanati; Effect of Romosozumab on Lumbar Spine and Hip Volumetric Bone Mineral Density (vBMD) as Assessed by Quantitative Computed Tomography (QCT) (Accepted for oral presentation Oct 5 2013 ASBMR)
12. HK Genant, TM Keaveny, C Zapalowski, K Engelke, T Fuerst, DL Kendler, **C. Recknor**, S Boonen, A Wang, P Dakin, C Libanati, MR McClung; Cortical Bone Parameters at the Hip in Response to Denosumab vs Placebo and the Clinical Relevance of These Changes in Postmenopausal Women With Osteoporosis <75 and ≥75 Years Old; (Submitted April 2013 ASBMR)
13. Stuart L Silverman, Ethel S Siris, David L Kendler, Dea Belazi, Jacques P Brown, Deborah T Gold, E Michael Lewiecki, Alexandra Papaioannou, Christine Simonelli, Irene Ferreira, Joseph J Pinzone, Suresh Siddhanti, Bradley Stolshek and **Christopher Recknor**; Baseline Characteristics and Design of a Prospective Observational Study in the United States and Canada to Evaluate Persistence With Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis, (ENDO poster presentation June 2013)
14. Ken Poole; Keaveny, Tony; Michael R. McClung, MD; David L Kendler ; **Christopher Recknor**; Steven Boonen; Libanati, Cesar; Wang, Andrea ; Denosumab Treatment Improves Hip Cortical Bone Parameters in Postmenopausal Women ≥75 Years With Osteoporosis in the FREEDOM Trial. (submitted)ASBMR March 2013
15. TM Keaveny, MR McClung, H Genant, JR Zanchetta, D Kendler, JP Brown, S Goemaere, **C. Recknor**, ML Brandi, R Eastell, DL Kopperdahl, K Engelke, T Fuerst, H Radcliffe, C Libanati, Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab, (submitted JBMR Feb 2013)
16. Bone histology and histomorphometry: effects of 5 years of denosumab (DMAb) in the FREEDOM extension, (Poster accepted ECTS 2013)
17. Zysset, Philippe, Pahr, Dieter, Engelke, Klaus, Genant, Harry, McClung, Michael R, Kendler, David L, "**Christopher Recknor**, Kinzl, Michael, Schwiedrzik, Jakob, Museyko, Oleg, Wang, Andrea,Libanati, Cesar, Estimation of Vertebral and Femoral Strength During the First Three Years of Denosumab Therapy Using an Alternative Smooth Non-linear Finite Element Methodology,(accepted for poster publication ECTS 2013 Congress, Lisbon Portugal May 2013)
18. Henry Bone, Rachel Wagman, **Christopher Recknor**, Edward Czerwinski, Suresh Siddhanti, Jesse Hall, Prayashi Ghelani, Prayashi, Irene Ferreira, Irene, mbolognese ,A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates, (submitted to ECCEO Jan 2013)
19. Silverman, Stuart L; Siris, Ethel S; Kendler, David L; Belazi, Dea; Brown, Jacques P ; Fox, John; Gold, Deborah T ; Lewiecki, EM; Papaioannou, Alexandra; Simonelli, Christine; Tolin, Fred; Ferreira, Irene; Pinzone, Joseph; Siddhanti, Suresh; Stolshek,

Brad; **Christopher Recknor**, ENDO 2013 Abstract - Denosumab Prospective Observational Study, submitted Nov 2012

20. Jean F. Lian, PhD, Xue Song,PhD, Helen Varker, BS, Zhun Cao, PhD, Christopher P. Recknor, MD, Novartis Pharmaceutical Corporation; Thompson Reuters; United Osteoporosis Centers, Gainesville, GA. Comparative Effectiveness Analysis Using "Real-World" Patient Database to Evaluate the Fractures Rates Comparing Annual Zoledronic Acid Infusion with Oral Bisphosphonates, poster accepted to ISPOR, (manuscript submitted to publishing)
21. David W Dempster, Hua Zhou, Robert R Recker, Jacques P Brown, Michael A Bolognese, **Christopher P Recknor**, David L Kendler, E Michael Lewiecki, David A Hanley, D Sudhaker Rao, Paul D Miller, Grattan C Woodson, III, Robert Lindsay, Neil Binkley, Xiaohai Wan, Valerie A Ruff, Boris Janos, Kathleen A Taylor, Differential Effects of Teriparatide and Zoledronic Acid on the Outer and Inner Surfaces of Cortical Bone in Postmenopausal Women with Osteoporosis: Results from the SHOTZ Trial, ASBMR 2012 (submitted)
22. Simon J, Recknor C, Moffet A, Adachi J, Franek E, Lewiecki M, Mautalen CA, Ragi Eis S, Nicholson G, Muschitz C, Nuti R, Torring O, Wang A, Libanati C. Effects of Denosumab on Radius BMD, Strength, and Wrist Fractures: Results from the Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Month (FREEDOM) Study. submitted poster for Germany DVO congress 2012.
23. Jesse W Hall, Paul D Miller, E Michael Lewiecki, Maria Luisa Brandi, Jonathan D. Adachi, **Christopher Recknor**, Andrea Wang, Steven Boonen, Leuven University, Leuven, Belgium; Colorado Center for Bone Research, Lakewood, CO, USA; New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA; Azienda Ospedaliera Careggi, Firenze, Italy; McMaster University, Hamilton, ON, Canada; United Osteoporosis Centers, Gainesville, GA, USA; Amgen Inc., Thousand Oaks, CA, USA. The Effects of Denosumab in Increasing Hip Bone Mineral Density in Older Versus Younger Women with Postmenopausal Osteoporosis. **AANP March 2012**
24. C Roux, JP Brown, J-E Beck Jensen, N Gilchrist, **C. Recknor**, O Tørring, M Austin, A Wang, A Grauer, P-R Ho, R Wagman. Denosumab discontinuation and associated fracture risk: A FREEDOM trial analysis. **EULAR12-1182, June 2012 Berlin (**Presented)
25. S Boonen, PD Miller, EM Lewiecki, ML Brandi, JD Adachi, **C. Recknor**, A Wang, JW Hall , Leuven University, Leuven, Belgium; Colorado Center for Bone Research, Lakewood, CO, USA; New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA; Azienda Ospedaliera Careggi, Firenze, Italy; McMaster University, Hamilton, ON, Canada; United Osteoporosis Centers, Gainesville, GA, USA; Amgen Inc., Thousand Oaks, CA, USA. Denosumab increases total hip bone mineral density in older women with postmenopausal osteoporosis. **ECCEO 2012-IOF12 (Presented)**
26. C Roux, JP Brown, J-E Beck Jensen, N Gilchrist, **C. Recknor**, O Tørring, M Austin, A Wang, A Grauer, P-R Ho, R Wagman. Denosumab discontinuation and associated fracture risk: A FREEDOM trial analysis. **ECCEO 2012-IOF12 (Submitted-Poster).**
27. O. Törring, J. Simon, **C. Recknor**, A. Moffet, J. Adachi, E. Franek, E. Lewiecki, C. Mautalen, S. Ragi Eis, G. Nicholson, C. Muschitz, R. Nuti, A. Wang, C. Libanati Karolinska Institutet Södersjukhuset, Stockholm, Sweden, 2. George Washington University, Washington DC, 3. United Osteoporosis Center, Gainesville, 4. OB-GYN

Associates of Mid Florida, Leesburg, United States, 5. St Joseph's Hospital, McMaster University, Hamilton, Canada, 6. Central Clinical Hospital MSWiA, Warsaw, Poland, 7. New Mexico Clinical Research & Osteoporosis Center and University of New Mexico School of Medicine, Albuquerque, United States, 8. Centro de Osteopatias Medicas, Buenos Aires, Argentina, 9. CEDOES Centro de Diagnostico e Pesquisa, Vitória, Brazil, 10. Barwon Health, The Geelong Hospital, Geelong, Australia, 11. St. Vincent Hospital, Vienna, Austria, 12. University of Siena, Siena, Italy, 13. Amgen Inc., Thousand Oaks, United States. Denosumab Effects on Radius BMD, Estimated Strength, and Wrist Fractures: 3-Year results From the FREEDOM Study. **ECTS12-1189, 2012 May Meeting.** (**Accepted for oral Poster Feb 2012)**

28. Lian J, Song X, Varker H, Cao Z, Recknor C
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Thomson Reuters, Cambridge, MA, USA, United Osteoporosis Centers, Gainesville, GA, USA
Comparative Effectiveness Analysis Using "Real-World" Patient Database To Evaluate The Fractures Rates Comparing Annual Zolendronic Acid infusion with Oral Bisphosphonates. **ISPOR 2012 17th Annual International Meeting.** (**Accepted as Poster Presentation, PMS3)**
29. Paul D Miller, E Michael Lewiecki, Maria Luisa Brandi, Jonathan D. Adachi, **Christopher Recknor**, Andrea Wang, Jesse W Hall, Steven Boonen. Efficacy of Denosumab in Increasing Hip Bone Mineral Density in Older Versus Younger Women with Postmenopausal Osteoporosis. ISCD March 2012: Pub ID: 1-5VF5K, poster 130.
30. Adachi JD, Lyles K, Boonen S, Colón-Emeric C, Hyldstrup L, Nordsletten L, Pieper C, Recknor C, Su G, Bucci-Rechtweg C, Magaziner J. Subtrochanteric Fractures in Bisphosphonate-Naive Patients: Results from the HORIZON-Recurrent Fracture Trial. Calcified Tissue International. 2011 Oct 30. PMID: 22038744 47J Brown, JE Beck-Jensen, N Gilchrist, **C. Recknor**, C Roux, O Torring, M Austin, A Wang, A Grauer, R Wagman. Discontinuation of Denosumab and Associated Fracture Incidence: Analysis From the FREEDOM Trial. ASBMR Pub ID: 1-3NGZA. **(2011 Pending)**.
31. **C. RecknorC. Recknor**, J. Recknor, P Sun, J Lian. The Analysis of Denosumab Discontinuation and Associated Fracture Incidence in the FREEDOM Trial. Oral presentation ACR/ARHP Nov 2011.
32. J Brown, JE Beck-Jensen, N Gilchrist, **C. Recknor**, C Roux, O Torring, M Austin, A Wang, A Grauer, R Wagman. Discontinuation of Denosumab and Associated Fracture Incidence: Analysis From the FREEDOM Trial. ASBMR Pub ID: 1-3NGZA. (2011).
33. Dempster D, Zhou H, Recker R, Brown J, Bolognese M, Recknor C, Kendler D, Lewiecki M, Hanley D, Rao D, Miller P, Woodson G, Lindsay R, Binkley N, Wan X, Ruff V, Janos B, Taylor K. Skeletal Histomorphometry in Patients On Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: 6-Month Results of a Randomized Clinical Trial. ASBMR Sept. 2011(Presented).
34. Simon J, Recknor C, Moffet A, Adachi J, Franek E, Lewiecki M, Mautalen CA, Ragi Eis S, Nicholson G, Muschitz C, Nuti R, Torring O, Wang A, Libanati C. Effects of Denosumab on Radius BMD, Strength, and Wrist Fractures: Results from the Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Month (FREEDOM) Study. ASBMR Pub ID: 1-49W5Y. Sept 16-20, 2011.
35. JD Adachi, KW Lyles, CS Colón-Emeric, S Boonen, CF Pieper, C Mautalen, L Hyldstrup, **C. Recknor**, L Nordsletten, C Bucci-Rechtweg, G Su, EF Eriksen, and JS

Magaziner. Zoledronic acid improves Health-related quality of life in patients with hip fracture: Results of HORIZON-RFT. Poster # P145. ECCEO 2011.

36. P. Hadji, J. R. Zanchetta, L. A. Russo, C. P. Recknor, K. G. Sagg, F. E.McKiernan, S. L Silverman, J. Alam, R. T Burge, J. H. Krege, M. L. Lakshmanan, D. N. Masica, B. H. Mitlak, J. L. Stock. Effect of Teriparatide Compared With Risedronate on Back Pain and Incident Vertebral Fractures in Postmenopausal Women With Osteoporotic Vertebral Fractures. Oral presentation # OC48 ECTS/IBMS11-ABS-1288. May 7-11, 2011.
37. H Genant, M McClung, J Zanchetta, D Kendler, JP Brown, S Goemaere, **C. Recknor**, ML Brandi, R Eastell, DL Kopperdahl, K Engelke, T Fuerst, H Radcliffe, C Libanati, T Keaveny. Denosumab Increases Total, Trabecular, and Cortical Estimated Hip and Spine Strength in Post-Menopausal Women with Osteoporosis. Poster # OPC01 ECTS/ IBMS11-ABS-1810. May 7-11, 2011.
38. H Genant, M McClung, J Zanchetta, D Kendler, JP Brown, S Goemaere, **C. Recknor**, ML Brandi, R Eastell, DL Kopperdahl, K Engelke, T Fuerst, H Radcliffe, C Libanati, T Keaveny. Denosumab Significantly Improves Total, Trabecular, and Cortical Estimated Strength at the Hip and Spine Over the Duration of the FREEDOM Trial. Oral Presentation for the International Society for Clinical Densitometry (ISCD) in 2011.
39. **C. Recknor**. Clinical Science Lecture: Physical Functional Performance as Related to Vertebral Fracture via Safe Functional Motion (SFM) Score. Oral Presentation for American Society for Bone and Mineral Research. October 16-19, 2010.
40. JD Adachi, KW Lyles, CS Colón-Emeric, S Boonen, CF Pieper, C Mautalen, L Hyldstrup, **C. Recknor**, L Nordsletten, C Bucci-Rechtweg, G Su, EF Eriksen, and JS Magaziner. Zoledronic acid improves Health-related quality of life in patients with hip fracture: Results of HORIZON-RFT. Poster # SA0396 American Society for Bone and Mineral Research. October 16-19, 2010.
41. F Cosman[1,2], EF Eriksen[3], **C. Recknor**[4], P Miller[5], SL Greenspan[6], P Papanastasiou[7], H Rao[8], J Gasser[7], C Bucci-Rechtweg[9], S Boonen[10] Effects of once-yearly zoledronic acid 5 mg in combination with teriparatide (PTH) on postmenopausal women with osteoporosis. ECTS 2010.
42. TM Keaveny, M McClung, H Genant, JR Zanchetta, D Kendler, JP Brown, S Goemaere, **C. Recknor**, ML Brandi, R Eastell, DL Kopperdahl, K Engelke, T Fuerst, H Radcliffe and C Libanati. Denosumab Improves Both Femoral and Vertebral Strength in Women with Osteoporosis: Results From the FREEDOM Trial. American Society for Bone and Mineral Research, Presentation Number: 1099, October 16-19, 2010.
43. JD Adachi, KW Lyles, CS Colón-Emeric, S Boonen, CF Pieper, C Mautalen, L Hyldstrup, **C. Recknor**, L Nordsletten, C Bucci-Rechtweg, G Su, EF Eriksen, and JS Magaziner. Zoledronic acid improves Health-related quality of life in patients with hip fracture: Results of HORIZON-RFT. Poster # P383. International Osteoporosis Foundation WCO- ECCEO10 Congress Florence, Italy, May 2010.
44. JR Zanchetta, A Høiseth, DL Kendler, CK Yuen, JP Brown, S Stonkus, S Goemaere, **C. Recknor**, G Woodson, MA Bolognese, E Franek, ML Brandi, A Wang, C Libanati, and M McClung. Denosumab Increased BMD of the Lumbar Spine, Total Hip, Femoral Neck, and Trochanter as Measured by QCT in Postmenopausal Women With Osteoporosis. Oral Presentation for the International Society for Clinical Densitometry (ISCD), 2010.
45. MR McClung P Miller, **C. Recknor** M-E Ruzycky, C Bucci-Rechtweg S Yu S and C-L Benhamou. Zoledronic acid (ZOL) prevents bone loss in postmenopausal women with

low bone mineral density (BMD): The HORIZON Prevention Study. Australian & New Zealand Bone & Mineral Society (ANZBMS), 2010.

46. Recknor C, Reid DM, Delmas P, Eastell R, Boonen S, Cummings S, Palermo L, Cauley J, Cosman F, Mesenbrink P, Kriegman A, Eriksen E, Black D. The addition of once-yearly zoledronic acid 5 mg to non-bisphosphonate treatment for osteoporosis reduced fractures in postmenopausal women: The HORIZON-Pivotal Fracture Trial. Presented at: North American Menopause Society 31st Annual Meeting; September 24–27, 2009; Orlando, Fl.
47. MR McClung, PD Miller, CP Recknor et al. Efficacy And Safety of Zoledronic Acid 5mg in the prevention of Osteoporosis In Postmenopausal Women With Osteopenia: The Horizon Prevention Study. Poster # 162. American Society for Bone and Mineral Research, 2009.
48. **C. Recknor**, S Grant, J Recknor, and NJ McIntyre. Novel Safe Functional Motion Test Can Discriminate Risk for Vertebral Fracture in Men and Women. American Society for Bone and Mineral Research, Presentation Number MO0310, 2009.
49. F Cosman, et. al., Effects of Once-Yearly Zoledronic Acid 5mg in Combination with Teriparatide (PTH) on Postmenopausal Women with Osteoporosis. American Society for Bone and Mineral Research, Sep 2009, Presentation Number 1025.
50. MR McClung, PD Miller, CP Recknor, et al. Efficacy And Safety of Zoledronic Acid In The Prevention Of Osteoporosis In Postmenopausal Women With Osteopenia: The Horizon Preventive Study. 8th International Symposium on Osteoporosis: Translating Research into Practice. Washington, D.C., NOF, 2009.
51. P. Aspenberg, H. K. Genant, T. Johansson, A. J. Nino, K. See, K. Krohn, P. Garcia, C. P. Recknor, T. A. Einhorn, G. P. Dalsky, M. Lakshmanan Effects of Teriparatide on Distal Radial Fracture Healing in Postmenopausal Women: a Randomized Double-blinded Study. Aspenberg ECTS 2008.
52. D. M. Reid, P. Delmas, R. Eastell, S. Boonen, S. Cummings, L. Palermo, J. Cauley, **C. Recknor**, F. Cosman, P. Mesenbrink, A. Kriegman, E. Eriksen, D. Black. The Addition of Once-Yearly Zoledronic Acid 5mg to Non-Bisphosphonate Treatment for Osteoporosis Reduced Fractures in Postmenopausal Women: The Horizon-Pivotal Fracture Trial. North American Menopause Society Meeting, 2008.
53. JA Reid DM, Devogelaer J-P, Saag K, Roux C, Lau CS, Reginster J-Y, Papanastasiou P, Ferreira A, Fashola T, Sambrook P, Recknor C. Single Infusion of Zoledronic Acid 5 mg Is Significantly More Effective Than Daily Oral Risedronate 5 mg in Increasing Bone Mineral Density of the Lumbar Spine, Hip, Femoral Neck, and Trochanter in Patients With Glucocorticoid-Induced Osteoporosis. American Academy of Family Practitioner's Annual Meeting, 2008.
54. C. Colón-Emeric, P. Mesenbrink, K.W. Lyles, C. Pieper, S. Boonen, P. Delmas, E. Eriksen, J. Magazine, **C. Recknor**. Potential Mediators of the Reduction in Mortality with Zoledronic Acid after Hip Fracture. American Society for Bone and Mineral Research, 2008.
55. P Mesenbrink, EF Eriksen (Steering Committee: K Lyles, S Boonen, C Colon-Emeric, **C. Recknor**, J Magaziner, C Pieper, L Nordsletten, L Hyldstrup and J Adachi. Relationship between hip fracture surgery and timing of 1st infusion and efficacy and safety endpoints. Eighth European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, Istanbul, Turkey. April 2008.

56. K Lippuner, R Eastell, I Reid, CL Benhamou, CRecknor, S Ish-Shalom, G Bianchi, D Black, P Mesenbrink, EF Eriksen, PD Delmas Effect of Previous Bisphosphonate Use on Response to Zoledronic Acid: Results from the HORIZON-PFT Study. International Bone & Mineral Society. Presentation # 132, 2008
57. J-Y Reginster, JLC Borges, **C. Recknor**, F Sedarati, C Neate, and F Cosman. Oral ibandronate (150mg) administered monthly provides similar improvements in hip bone mineral density as oral alendronate (70mg) administered weekly in postmenopausal osteoporosis. American College of Rheumatology, 2007 Poster.
58. L Nordsletten, K Lyles, **C. Recknor** et.al. Efficacy/Safety of Zoledronic Acid 5 mg in Preventing Fractures in Men and Women After Hip Fracture. Academy of Orthopaedic Surgeons, Oral Presentation # 106, 2007.
59. F Cosman, R Wermers, **C. Recknor**, K Mauck, L Xie, E Glass and J Krege Efficacy of Adding Teriparatide versus Switching to Teriparatide in Postmenopausal Women with Osteoporosis Previously Treated with Raloxifene or Alendronate. Poster for the American Society for Bone and Mineral Research, 2007.
60. K. Krohn, R.A. Adler, J.P. Devogelaer, **C. Recknor**, K. See1, M. Wong1, D. Agnusdei1. Effects of Glucocorticoid Dose on the BMD Response to Teriparatide or Alendronate American Society for Bone and Mineral Research, 2007.
61. K. Krohn, R.A. Adler, J.P. Devogelaer, **C. Recknor**, K. See1, M. Wong1, D. Agnusdei1. Effects of Glucocorticoid Dose on the BMD Response to Teriparatide or Alendronate Therapy 5th International Congress on Glucocorticoid Induced Osteoporosis, 2007.
62. **C. Recknor** R Adler, N. Casas, JP Devogelaer, K See, M Wong, K Krohn. BMD Response to Teriparatide or Alendronate Therapy in Patients with Glucocorticoid-Induced Osteoporosis. Annual Scientific Meeting of the American College of Rheumatology, Abstract # 2297, 2007.
63. **C. Recknor**. Quarterly Intravenous Ibandronate Injections Provide Continuing Benefits in Women with Postmenopausal Osteoporosis: DIVA Study Long-Term Extension. American Society for Bone and Mineral Research, Abstract #1508, Oral Presentation #W363, 2007.
64. D. M. Black, **C. Recknor**, P. Delmas, R. Eastell, I. Reid, S. Boonen, J. Cauley, F. Cosman, P. Lakatos, P. C. Leung, Z. Man, E. F. Eriksen, P. Mesenbrink, T. Hue,1 S. Cummings, for the HORIZON-Pivotal Fracture Trial (PFT) Research Group. Effect of Once-Yearly Infusion of Zoledronic Acid 5 mg in Postmenopausal Women With Osteoporosis Infusion Nurse Society Annual Meeting, 2007.
65. **C. Recknor** and S Grant. Balance Dysfunction And Osteoporosis: A Prevalence Study Of Balance Dysfunction Causes. The National Osteoporosis Foundation, 7th International Symposium on Osteoporosis, Presentation Number 64, 2007.
66. K. W. Lyles, C. S. Colon-Emeric, C. Pieper, J. Caminis, F. Hartl, P. Mesenbrink, C. Mautalen, S. Boonen, **C. Recknor**, K. Moore, R. Adachi, J. Magaziner J. Zhang. The Horizon Recurrent Clinical Fracture After Recent Hip Fracture Trial (Rft) Study Cohort Description. The American Society For Bone And Mineral Research, Presentation Number: SA405, 2006.
67. M. Luckey, J. P. Bilezikian, R. Lindsay, K. Saag, **C. Recknor**, D. Cahall, R. Adachi, A. Hodsman, P. Miller. Impact of Prior Bisphosphonate Therapy on the Anabolic Effects of Teriparatide: Baseline Data for Subjects Enrolled in the OPTAMISE Study. American Society for Bone and Mineral Research, Presentation Number: M348, 2006.

68. D. Felsenberg, **C. Recknor**, X. Zhou, A. Grauer. Predicting Vertebral Fractures: Small Vertebral Deformities Increase the Risk of Subsequent Vertebral Fracture at One Year - Fast and Effective Risk Reduction with Risedronate. American Society for Bone and Mineral Research, Presentation Number: SU013, 2006.
69. **C. Recknor**, S. Grant*, L. Short, R. Wherry, A. Reisman, C. Ratchford, E. Hendricks, M. Gibbs, D. Fordham, E. Campbell. Test Use of a New Osteoporosis Medication Adherence Questionnaire. American Society for Bone and Mineral Research, Presentation Number: SU293, 2006.
70. R. Civitelli, **C. Recknor**, C. E. Barr, N. Lane, M. Zaidi. Continued Improvements in Bone Mineral Density in Women with Postmenopausal Osteoporosis Following 1 and 2 years of Intravenous Ibandronate Therapy. American Society for Bone and Mineral Research, Presentation Number: 1049, 2006.
71. R Wermers, **C. Recknor**, F Cosman, L Xie, Glass EV, Krege JH Effects of Teriparatide on Serum Calcium in Postmeopausal Women with Osteoporosis Previously Treated with Raloxifene or Alendronate. European Calcified Tissue Symposium, 2006.
72. M Zaidi, **C. Recknor** , WP Olszynski, C Leigh, I Jonkanski, D Masanauskaite, PN Sambrook. Safety and tolerability profile of intravenous ibandronate injection is similar to daily oral dosing: DIVA 2-year analysis. International Osteoporosis Foundation, World Congress on Osteoporosis, 2006.
73. EM Lewiecki, M Zaidi, M Drezner and **C. Recknor**. Intermittent intravenous ibandronate injections are at least as effective as daily oral ibandronate: 1-year DIVA results. Poster for the North American Menopause Society, 2005.
74. R Recker, D Kendler, **C. Recknor**, T Rooney, EM Lewiecki, WH Utian, J Cauley, J Lorraine, Y Qu, PM Kulkami, L Plouffe, JL Stock. Effects of Raloxifene or Alendronate on Fracture Risk Reduction: Results from the EVA (Evista©/Alendronate Comparison) Trial. Poster for the American Society for Bone and Mineral Research, Presentation Number: F425, 2005.
75. **C. Recknor**, S Grant, J Empert, F Bride, M Shotwell, B Schell. Bone Safety Evaluation: Balance Domain Validation. American Society for Bone and Mineral Research, Presentation Number: SU444, 2005.
76. **C. Recknor**,, S Grant, , J Catanzarite, K Mohr, L Benson, T Bateman, Bone Safety Evaluation and Functional Risk for Fracture Index. The National Osteoporosis Foundation, 6th International Symposium on Osteoporosis. 2005.
77. **C. Recknor**, TA Brosky II and S Grant. The effect of teriparitide [human parathyroid hormone (1-34)] therapy on fracture healing in Charcot neuroarthropathy of the lower extremity. The National Osteoporosis Foundation, 6th International Symposium on Osteoporosis. 2005.
78. **C. Recknor** and AB Klemes. Vertebroplasty: Insufficient Diagnosis and Treatment of Osteoporosis Post Procedure. American Society for Bone and Mineral Research, Presentation Number: SA367, 2004.

Publications:

1. Denise Orwig, Kenneth Lyles, Lars Nordsletten, Steven Boonen, Johnathan Adachi, Christopher Recknor, Cathleen Colón-Emeric, Peter Mesenbrink, Christina Bucci-Rechtweg, Guoqin Su, Rasheeda Johnson,Carl Pieper; Subgroup Variations in Bone Mineral Density Response to Zoledronic Acid Following Hip Fracture, Submitted JBMR May 2014
2. N. J. MacIntyre, C.P. Recknor, S.L. Grant, J.C. Recknor, Scores on the Safe Functional Motion test predict incident vertebral compression fractures, August 2013, Osteoporosis International
3. Norma J. MacIntyre, Chris P. Recknor and Julie C. Recknor; Spine curve measures taken in individuals with osteoporosis and osteopenia using the IONmed mobile phone application are highly consistent with digital inclinometer measures; (accepted for publication ISRN Rehabilitation Dec 2013)
4. Jacques P. Brown, MD; Christian Roux; Pei-Ran Ho; Michael A. Bolognese; Jesse Hall; Henry G. Bone; Sydney Bonnick; Joop P. van den Bergh; Irene Ferreira; Paula Dakin; Rachel B. Wagman; **Christopher Recknor**; Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate. Osteoporosis International, (submitted December 2013)
5. **Chris Recknor**, MD, ONG-12-1845R1, Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy: Efficacy and Safety Results From a Randomized Open-label Study. Obsterics & Gynecology (June 2013)
6. Jacques P Brown, MD, Christian Roux, MD, PhD, Ove Törring, MD, PhD, Pei-Ran Ho, MD, Jens-Erik Beck Jensen, MD, PhD, Nigel Gilchrist, MD, **Christopher Recknor**, MD,Matt Austin, MS, Andrea Wang, MA, Andreas Grauer, MD, Rachel B Wagman, MD Discontinuation of Denosumab and Associated Fracture Incidence: AnalysisFrom the FREEDOM Trial. Journal of Bone and Mineral Research (Accepted for publication Nov 2012) Publication May 2013
7. J. Simon, **C. Recknor**, A. Moffett, J. Adachi, E. Franek, E. Lewiecki, M. McClung, C. Mautalen, S. Ragi-Eis, G. Nicholson, C. Muschitz, R. Nuti, O. Törring, A. Wang, C. Libanati, Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. Menopause Feb. 2013: 130-137
8. Dempster, DW, Zhou H, Recker RR, Brown JP, Bolognese MA, **Recknor CP**, Kendler DL, Lewiecki EM, Hanley DA, Rao DS, Miller PD, Woodson GC, Lindsay R, Binkley N, Wan X, Ruff VA, Janos B, Taylor KA. Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy(SHOTZ) study: a randomized controlled trial. J Clin Endocrinol Metab. 2012; doi:10.1210/jc.2012-1262.
9. Michael R. McClung, Jose R. Zanchetta, Arne Høiseth, David L. Kendler, Chui Kin Yuen, Jacques P. Brown, Sigitas Stonkus, Stefan Goemaere, **Chris Recknor**, Grattan C. Woodson, Michael A. Bolognese, Edward Franek, Maria Luisa Brandi, Andrea Wang, Cesar Libanati. Denosumab Densitometric Changes Assessed by Quantitative Computed Tomography at the Spine and Hip in Postmenopausal Women With Osteoporosis. Journal of Clinical Densitometry 2012 (accepted Feb 2012)

10. Peyman Hadji, José R. Zanchetta, Luis Russo, **Christopher P. Recknor**, Kenneth G. Saag, Fergus E. McKiernan, Stuart L. Silverman, Jahangir Alam, Russel T. Burge, John H. Krege, Mark L. Lakshmanan, Daniel N. Masica, Bruce H. Mitlak, John L. Stock. Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis. Osteoporosis International Online, Dec 2011
11. JD Adachi, KW Lyles, CS Colón-Emeric, S Boonen, CF Pieper, C Mautalen, L Hyldstrup, **C. Recknor**, L Nordsletten, C Bucci-Rechtweg, G Su, EF Eriksen, and JS Magaziner. Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON–Recurrent Fracture Trial, Osteoporosis International: Volume 22, Issue 9 (2011), Page 2539-2549
12. Cosman, F., Eriksen, E.F., **Christopher Recknor**., Miller, P.D., Guañabens, N., Kasperk, C., Papanastasiou, P., Readie, A., Rao, H., Gasser, J.A., Bucci-Rechtweg, C., Boonen, S. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis Journal of Bone and Mineral Research volume 26, issue 3, year 2011, pp. 503 - 511
13. Peyman Hadji, José R. Zanchetta, Luis Russo, **Christopher P. Recknor**, Kenneth G. Saag, Fergus E. McKiernan, Stuart L. Silverman, Jahangir Alam, Russel T. Burge, John H. Krege, Mark L. Lakshmanan, Daniel N. Masica, Bruce H. Mitlak, John L. Stock. · Effect of Teriparatide Compared with Risedronate on Reduction of Back Pain in Postmenopausal Women with Osteoporotic Vertebral Fractures. Journal of Bone and Mineral Research. MS# : M11050281 [Pending pub. (Submitted May 2011)]
14. J Adachi, K Lyles, S Boonen, C Colon-Emeric, L Hyldstrup, L Nordsletten, C Pieper, **C. Recknor**, G Su, C Bucci-Rechtweg, J Magaziner. Subtrochanteric Fractures in Bisphosphonate –Naïve patients: Results from the Horizon-Recurrent Fracture Trial. Calcified Tissue International. [Pending publication (Re-submitted Apr 2011)].
15. Sambrook P, Silverman S, Cauley J, Recknor C, Olson M, Su G, Boonen S. Black D, Adachi J. Health-Related Quality of Life and Treatment of Postmenopausal Osteoporosis: Results from the HORIZON–PFT. BONE (2011), doi:10.1016/j.bone.2011.03.719
16. Peyman Hadji, José R. Zanchetta, Luis Russo, **Christopher P. Recknor**, Kenneth G. Saag, Fergus E. McKiernan, Stuart L. Silverman, Jahangir Alam, Russel T. Burge, John H. Krege, Mark L. Lakshmanan, Daniel N. Masica, Bruce H. Mitlak, John L. Stock. · Effect of Teriparatide Compared with Risedronate on Reduction of Back Pain in Postmenopausal Women with Osteoporotic Vertebral Fractures. New England Journal of Medicine. ID: 11-03772 [Pending pub (Submitted Apr 2011)]
17. **Christopher Recknor**; Zoledronic Acid for Prevention and Treatment of Osteoporosis. Expert Opinion on Pharmacotherapy. ID # EOOP-2010-0327.R1. (2011) 12(5):1-9. 31**,** Sambrook P, Silverman S, Cauley J, **Recknor C**, Olson M, Su G, Boonen S. Black D, Adachi J. Health-related quality of life and treatment of postmenopausal osteoporosis: Results from the HORIZON –PFT. Journal of the American Geriatrics Society. [Pending publication. (Submitted 12/13/10)]
18. J Adachi, K Lyles, S Boonen, C Colon-Emeric, L Hyldstrup, L Nordsletten, C Pieper, **C. Recknor**, G Su, C Bucci-Rechtweg, J Magaziner. Subtrochanteric Fractures in Bisphosphonate –Naïve patients: Results from the Horizon-Recurrent Fracture Trial. Osteoporosis International. Pending publication.

19. Sambrook P, Silverman S, Cauley J, **Recknor C**, Olson M, Su G, Boonen S. Black D, Adachi J. Health-related quality of life and treatment of postmenopausal osteoporosis: Results from the HORIZON –PFT. Osteoporosis International. 2010. Pending publication.
20. Effects of Intravenous Zoledronic Acid Subcutaneous Teriparatide [(1-34)rhPTH] in Postmenopausal Osteoporosis. Journal of Bone Bone Mineral Research MS# J100426
21. Colón-Emeric C, Nordsletten L, Olson S, Major N, Boonen S, Haentjens P, Mesenbrink P, Magaziner J. Adachi J, Lyles KW, Hyldstrup L, Bucci-Rechtweg C, **Recknor C ;** Association between Timing of Zoledronic Acid Infusion and Hip Fracture Healing. Osteoporosis International. 2010. DOI: 10.1007/s00198-010-1473-1. Available at: http://www.springerlink.com/content/w88n43n1v4277662/fulltext.pdf
22. J. D. Adachi, K. W. Lyles, C. S. Colón-Emeric, S. Boonen, C. F. Pieper, C. Mautalen, L. Hyldstrup, **C. Recknor**, L. Nordsletten and K. A. Moore, et al. Zoledronic Acid Results in Better Health-Related Quality of Life Following Hip Fracture: The HORIZON-Recurrent Fracture Trial. Osteoporosis International. Volume 22, Issue 9 (2011), Page 2539-2549.
23. Zanchetta JR, Hoiseth A, Kendler DL, Yuen CK, Brown JP, Stonkus S, Kaufman JM, **Recknor C**, Woodson G, Bolognese MA, Franek E, Brandi ML, Wang A, Libanati C, McClung MR. Denosumab Increased BMD of the Lumbar Spine, Total Hip, Femoral Neck, and Trochanter as Measured by QCT in Postmenopausal Women With Osteoporosis. 2009. Publication Pending.
24. **Recknor C**, Grant S, MacIntyre N, Recknor J. Safe Functional Motion test predicts prevalent osteoporotic fractures and injurious falls. 2010. Pending publication.
25. Wark JD, Bensen W, **Recknor C**, Ryabitseva O, Chiodo III J, Mesenbrink P, De Villiers TJ Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. 2009 Osteoporosis International. OI-2010-08-0547.R1
26. Magaziner, etal. Bone Mineral Density following hip fracture : Variations in response to Zoledronic Acid. Pending Publication in Annals of Internal Medicine, 2009.
27. Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for Acceleration of Fracture Repair in Humans: A Prospective, Randomized, Double-blind Study of 102 Postmenopausal Women with Distal Radial Fractures. Journal of Bone Mineral Research 2009. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19594305 [Accessed April 26, 2010].
28. McClung M, Miller P, **Recknor C**, et al. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstetrics & Gynecology 2009;114(5):999-1007.
29. Devogelaer J, Adler RA, Recknor C, et al. Baseline Glucocorticoid Dose and Bone Mineral Density Response with Teriparatide or Alendronate Therapy in Patients with Glucocorticoid-induced Osteoporosis. The Journal of Rheumatology 2009. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19918047 [Accessed November 30, 2009].
30. Cosman F, Wermers RA, Recknor C, et al. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. The Journal of Clinical Endocrinology Metabolism. 2009;94(10):3772-3780.
31. Emkey R, Delmas PD, Bolognese M, Borges JLC, Cosman F, Ragi-Eis D, **Recknor C**, Zerbini CA, Neate C, Sedarati F, Epstein S. Efficacy and Tolerability of Once-Monthly Oral Ibandronate (150 mg) and Weekly Oral Alendronate (70 mg): Results from a Head-to-Head Study (MOTION). Clincal Therapeutics 2009;31:751–761.

32. **Recknor C** and Grant S and MacIntyre NJ. A Novel Performance-Based Measure Of Functional Risk For Osteoporotic Fracture Has Excellent Reliability And Good Convergent Construct Validity. Osteoporosis International, 2009; 20(2), S226-S227.
33. Grant S, **Recknor C** and MacIntyre NJ. Validity Of The Strength And Flexibility Domains Comprising A Novel Performance-Based Measure Of Functional Risk For Osteoporotic Fracture. Osteoporosis International, 2009; 20(2), S226.
34. McCLung MR, Miller PD, **Recknor CP**, et al. Efficacy And Safety Of Zoledronic Acid In The Prevention Of Osteoporosis In Postmenopausal Women With Osteopenia: The Horizon Preventive Study. Osteoporosis International, 2009; 20(2), S212-S213.
35. Eriksen EF, Lyles KW, Colón-Emeric CS, et al. Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. Journal of Bone and Mineral Research 2009;24(7):1308-1313.
36. **Recknor C** and Grant S. Bone Safety Evaluation: Validation of a Safe Functional Motion Test. Manuscript under development. 2009
37. Wermers R, Cosman F, **Recknor C**, et al. Measuring serum calcium before and after teriparatide treatment: authors' response. Osteoporosis International 2008. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18763008 [Accessed October 13, 2008].
38. Wermers RA, **Recknor CP**, Cosman F, et al. Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate. Osteoporosis International 2008;19(7):1055-65.
39. Eisman JA, Civitelli R, Adami S, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. The Journal of Rheumatology 2008;35(3):488-97.
40. **Recknor C.** Osteoporosis Management: Healthcare Crisis or Opportunity? Presentation to Women in Government 2008, http://devchronicdisease.i4a.com/files/public/808WIGOLTRecknor.pdf
41. Recknor C. Emerging Therapies in Osteoporosis. Physician's Weekly. 2008;25(4). Available at: http://www.physiciansweekly.com
42. Grbic JT, Landesberg R, Lin S, et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. Journal of American Dental Association 2008;139(1): 32-40.
43. **Recknor C**, Grant S. Balance Dysfunction and Osteoporosis: A prevalence study of balance dysfunction causes. Osteoporosis International 2007;18(0):193-244.
44. Recker RR, Kendler D, **Recknor CP**, et al. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone. 2007;40(4):843-51.
45. Recknor C, Falany A, Hulse M. Management of Hyperhomocysteinemia in Women. The Female Patient. 2007;32(2).
46. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S. Zoledronic; Acid in Reducing Clinical Fracture and Mortality after Hip Fracture. New England Journal of Medicine 2007; 357: 1799-1809.

Editorial Appointments
Aging Health (2009 to present) – Peer reviewer
HealthSouth Gainesville Surgery Center (2004 to present); Bone Biopsies (2004 to present)

Hospital Appointments/Clinic Priviledges
Northeast Georgia Medical Center (1995 to present); Bone Biopsies (2000 to present)
HealthSouth Gainesville Surgery Center (2004 to present); Bone Biopsies (2004 to present)

Bone Biopsy Experience

Postgraduate Training in Methods
Emory University Medical Center, Training with Nelson Watts, MD (1999 – 2001)
Angers, France, Training with Dr. Daniel Chappard (2005)

Bone Biopsy Instructor
University Hospital, Monterrey, Mexico (June 2005). Instructed Novartis Investigators in bone biopsy techniques for clinical trials.

Gainesville, GA (October 2005). Instructed North American and European Novartis Investigators in bone biopsy techniques for clinical trials.

Gainesville, GA (August 2006). Instructed South American NPS Investigators in bone biopsy techniques for clinical trials.

Memberships in Professional / Scientific Societies
American Society of Bone and Mineral Research
International Society for Clinical Densitometry
National Osteoporosis Foundation
Regional/Osteoporosis Board: Alliance for Better Bone Health